{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:57:14Z","timestamp":1768978634849,"version":"3.49.0"},"reference-count":31,"publisher":"ALUNA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:p>Aim: The current study designed to evaluate the abnormal expression prevalence of Cluster of Differentiation (CD) markers in Iraqi patients diagnosed with AL at the Medical City Hospitals.\nMaterials and Methods: A total of 175 newly diagnosed leukemia patients (110 males and 65 females) aged between 1 and 85 years were included. Bone marrow aspiration and flow cytometry were used to analyze CD marker expression. Data on hematological parameters, immunophenotypic profiles, and demographic characteristics were recorded and statistically analyzed.\nResults: The present study identified aberrant expression of CD markers, including CD13, CD19, CD33, CD34, CD117, CD56, CD5, TdT, HLA-DR, and CD79a, across different leukemia subtypes. Acute myeloid leukemia (AML) was the most prevalent subtype (46.2%), followed by B-acute lymphoblastic leukemia (B-ALL) (26.2%) and T-acute lymphoblastic leukemia (T-ALL) (8.5%). CD34 was highly expressed in AML, B-ALL, and T-ALL cases, while CD13 and CD33 were predominantly expressed in AML. CD56 and CD117 were associated with multiple myeloma (MM).\nConclusions: The study demonstrated a high ratio of abnormal CD marker expression in AL cases, aligning previous data from various area around the world. Identifying aberrant antigen expression patterns through immunophenotyping aids in diagnosing leukemia and distinguishing neoplastic cells from normal hematopoietic precursors.<\/jats:p>","DOI":"10.36740\/merkur202506104","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:25:33Z","timestamp":1768929933000},"page":"734","source":"Crossref","is-referenced-by-count":0,"title":["Aberrant expression of CD markers in patients with acute leukemia"],"prefix":"10.36740","author":[{"given":"Aymen Radhi","family":"Habeeb","sequence":"first","affiliation":[{"name":"DIRECTORATE OF EDUCATION OF RASAFA, MINISTRY OF EDUCATION, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"AL-Tameemi","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF MEDICAL LABORATORY TECHNIQUES, BILAD ALRAFIDAIN UNIVERSITY COLLAGE, BAQUBAH, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina A.A.","family":"Abdullah","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF SCIENCE, COLLEGE OF BASIC EDUCATION, UNIVERSITY OF DIYALA, BAQUBAH, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rand Muhammed Abdul-Hussein","family":"Al-Hussein","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF BIOLOGY, FACULTY OF SCIENCE, UNIVERSITY OF KUFA, NAJAF, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Khudhair","family":"Ahmed","sequence":"additional","affiliation":[{"name":"MINISTRY OF HEALTH & ENVIRONMENT, IRAQ; HEAMATOLOGY AND BONE MARROW CENTER, BAGHDAD MEDICAL CITY, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Petrov I, Suntsova M, Mutorova O, Sorokin M, et al. Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells. Aging (Albany NY). 2016;8(11):2936. doi: 10.18632\/aging.101102. DOI: 10.18632\/aging.101102","DOI":"10.18632\/aging.101102"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. AL-Tameme HK, AL-Husseini RM, AL-Mudhafer RH. Molecular study of TP53 exon 5 and their role in P53 expression in patients with colorectal carcinoma. In AIP Conf. Proc. 2023;2475(1). doi.org\/10.1063\/5.0102765. DOI: 10.1063\/5.0102765","DOI":"10.1063\/5.0102765"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Lewis RE, Cruse JM, Sanders CM, Webb RN, Suggs JL. Aberrant expression of T-cell markers in acute myeloid leukemia. Exp Mol Pathol. 2007;83(3):462-3. doi.org\/10.1016\/j.yexmp.2007.08.010. DOI: 10.1016\/j.yexmp.2007.08.010","DOI":"10.1016\/j.yexmp.2007.08.010"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Vafaie M, Sadeghi H, Khoei SG. Immunophenotyping of Childhood Acute Lymphoblastic Leukemia in Qazvin City, Iran: A Cross-Sectional Study. J Inflamm Dis. 2023;26(4):209-16. doi.org\/10.32598\/JID.26.4.6. DOI: 10.32598\/JID.26.4.6","DOI":"10.32598\/JID.26.4.6"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Sarma A, Hazarika M, Das D, Kumar Rai A, et al. Expression of aberrant CD markers in acute leukemia: A study of 100 cases with immunophenotyping by multiparameter flowcytometry. Cancer Biomark. 2015;15(4):501-5. doi.org\/10.3233\/CBM-15048. DOI: 10.3233\/CBM-150482","DOI":"10.3233\/CBM-150482"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Salem DA, Abd El-Aziz SM. Flowcytometric immunophenotypic profile of acute leukemia: mansoura experience. Indian J Hematol Blood Transfus. 2012;28:89- 96. doi.org\/10.1007\/s12288-011-0110-2. DOI: 10.1007\/s12288-011-0110-2","DOI":"10.1007\/s12288-011-0110-2"},{"key":"ref6","unstructured":"7. Choudhury R, Sreevalli A, Balakrishnan CH, Ross CR. Clinical and laboratory profile of acute leukemia with special reference to flow cytometry. Med Innov. 2017;6(2). doi.org\/10.1007\/s12288-011-0110-2."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Ouyang G, Xu Z, Jiang D, Zhu H, et al. Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia. JIMR. 2019;47(4):1483-92. doi.org\/10.1177\/03000605188196. DOI: 10.1177\/0300060518819637","DOI":"10.1177\/0300060518819637"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Balasubramanian M, Sangoi NN. Utility of Bone Marrow Examination in Pediatric Age Group: Experience of a Tertiary Healthcare Centre in India. Cureus. 2022;14(7). doi: 10.7759\/cureus.27056. DOI: 10.7759\/cureus.27056","DOI":"10.7759\/cureus.27056"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Ahmad S, Shah KA, Hussain H, Haq AU, Ullah A, Khan A, et al. Prevalence of acute and chronic forms of leukemia in various regions of Khyber Pakhtunkhwa, Pakistan: needs much more to be done! BJMS. 2019;18(2):222-7. doi.org\/10.3329\/bjms.v18i2.40689. DOI: 10.3329\/bjms.v18i2.40689","DOI":"10.3329\/bjms.v18i2.40689"},{"key":"ref10","unstructured":"11. Rathee R, Vashist M, Kumar A, Singh S. Incidence of acute and chronic forms of leukemia in Haryana. Int J Pharm Pharm Sci. 2014;6(02):323-5."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Amini M, Sharma R, Jani C. Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020. Arch Public Health. 2023;81(1):151. doi.org\/10.1186\/s13690-023-01154-8. DOI: 10.1186\/s13690-023-01154-8","DOI":"10.1186\/s13690-023-01154-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Resn NS, Zedan ZK. Impact of Chemotherapy on the hematological parameters of Acute Myeloid Leukemia Iraqi patients. JOBRC. 2024;18(2):103-11. doi.org\/10.24126\/jobrc.2024.18.2.807. DOI: 10.24126\/jobrc.2024.18.2.807","DOI":"10.24126\/jobrc.2024.18.2.807"},{"key":"ref13","unstructured":"14. Abuhelwa Z, Al Shaer Q, Taha S, Ayoub K, Amer R. Characteristics of de novo acute myeloid leukemia patients in Palestine: experience of An-Najah National University Hospital. Asian Pac J Cancer Prev. 2017;18(9):2459. doi: 10.22034\/APJCP.2017.18.9.2459."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology 2013, the American Society of Hematology Education Program Book. 2013;2013(1):220-6. doi.org\/10.1182\/asheducation-2013.1.220. DOI: 10.1182\/asheducation-2013.1.220","DOI":"10.1182\/asheducation-2013.1.220"},{"key":"ref15","unstructured":"16. Hikmat A, Salih S, Issa Y. Characterization of CD marker expression in acute myeloid leukemia. JMAUC. 2023;15(2):38-44."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. kareem Shwani L, Muhammad NS, Hamza HH. Evaluation of aberrant expression of CD markers in acute leukemia cells. Zanco J Med Sci. 2023;27(2):194-204. doi.org\/10.15218\/zjms.2023.022 DOI: 10.15218\/zjms.2023.022","DOI":"10.15218\/zjms.2023.022"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Soslow RA, Bhargava V, Warnke RA. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma\/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Human Pathol. 1997;28(10):1158-65. doi.org\/10.1016\/S0046-8177(97)90254-9. DOI: 10.1016\/S0046-8177(97)90254-9","DOI":"10.1016\/S0046-8177(97)90254-9"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Wang Y-Z, Hao L, Chang Y, Jiang Q, Jiang H, Zhang L-P, et al. A seven-color panel including CD34 and TdT could be applied in> 97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. Leuk Res. 2018;72:12-9. doi.org\/10.1016\/j.leukres.2018.07.012. DOI: 10.1016\/j.leukres.2018.07.012","DOI":"10.1016\/j.leukres.2018.07.012"},{"key":"ref19","unstructured":"20. Gupta R, Garg N, Kotru M, Kumar D, Pathak R. Immunophenotypic characteristics of T lineage acute lymphoblastic leukemia: absence of immaturity markers-TdT, CD34 and HLADR is not uncommon. Am. J. Blood Res. 2022;12(1):1."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Scolnik MP, Morilla R, de Bracco MaMdE, Catovsky D, Matutes E. CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leuk Res. 2002;26(7):615-9. doi.org\/10.1016\/S0145-2126(01)00182-5. DOI: 10.1016\/S0145-2126(01)00182-5","DOI":"10.1016\/S0145-2126(01)00182-5"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Aqil B, Gao J, Stalling M, Sukhanova M, et al. Distinctive flow cytometric and mutational profile of acute myeloid leukemia with t (8; 16)(p11; p13) translocation. Am. J. Clin. Pathol. 2022;157(5):701-8. doi.org\/10.1093\/ajcp\/aqab178 DOI: 10.1093\/ajcp\/aqab178","DOI":"10.1093\/ajcp\/aqab178"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Aanei C-M, Veyrat-Masson R, Rigollet L, Stagnara J, Tavernier Tardy E, Daguenet E, et al. Advanced flow cytometry analysis algorithms for optimizing the detection of \u201cdifferent from normal\u201d immunophenotypes in acute myeloid blasts. Front Cell Dev Biol. 2021;9:735518. doi.org\/10.3389\/fcell.2021.735518. DOI: 10.3389\/fcell.2021.735518","DOI":"10.3389\/fcell.2021.735518"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Herrmann H, Sadovnik I, Eisenwort G, Rulicke T, et al. Delineation of target expression profiles in CD34+\/CD38- and CD34+\/CD38+ stem and progenitor cells in AML and CML. Blood Adv. 2020;4(20):5118-32. doi.org\/10.1182\/bloodadvances.2020001742 DOI: 10.1182\/bloodadvances.2020001742","DOI":"10.1182\/bloodadvances.2020001742"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Mosleh M, Mehrpouri M, Ghaffari S, Saei Z, Agaeipoor M, Jadali F, et al. Report of a new six-panel flow cytometry marker for early differential diagnosis of APL from HLA-DR negative Non-APL leukemia. Scand J Clin Lab Invest. 2020;80(2):87-92. doi.org\/10.1080\/00365513.2019.1700427. DOI: 10.1080\/00365513.2019.1700427","DOI":"10.1080\/00365513.2019.1700427"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. El-Meligui YM, Abd Elrhman HE, Salahuddin A, Hamouda MA, Kassem AB. Correlation study on HLA-DR and CD117 (c-kit) expressions: Its prognosis and treatment response in acute myeloid leukemia patients. Pharm. genomics pers. med. 2021:381-93. doi.org\/10.2147\/PGPM.S268986. DOI: 10.2147\/PGPM.S268986","DOI":"10.2147\/PGPM.S268986"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Yu X, Li P, Feng H, Kang J, et al. CD22 Gating for Flow Cytometric Analysis in Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia after CD19 CAR-T Therapy. Blood. 2020;136:13. doi.org\/10.1182\/blood-2020-139341. DOI: 10.1182\/blood-2020-139341","DOI":"10.1182\/blood-2020-139341"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28. Bueno C, Barrera S, Bataller A, Ortiz-Maldonado V, et al. CD34+ CD19\u2212 CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood, Am. J. Hematol. 2022;140(1):38-44. doi.org\/10.1182\/blood.2021014840. DOI: 10.1182\/blood.2021014840","DOI":"10.1182\/blood.2021014840"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Cottini F, Rodriguez J, Hughes T, Sharma N, Guo L, Lozanski G, et al. Redefining CD56 as a biomarker and therapeutic target in multiple myeloma. Mol Cancer Res. 2022;20(7):1083-95. doi.org\/10.1158\/1541-7786.MCR-21-0828. DOI: 10.1158\/1541-7786.MCR-21-0828","DOI":"10.1158\/1541-7786.MCR-21-0828"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30. Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12(12):1977-82. doi.org\/10.1038\/sj.leu.2401211. DOI: 10.1038\/sj.leu.2401211","DOI":"10.1038\/sj.leu.2401211"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31. Escribano L, Ocqueteaub M, Almeida J, Orfao A, Migue JFS. Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis. Leuk Lymphoma. 1998;30(5-6):459-66. doi.org\/10.3109\/10428199809057558. DOI: 10.3109\/10428199809057558","DOI":"10.3109\/10428199809057558"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:03:38Z","timestamp":1768932218000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i6net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":31,"URL":"https:\/\/doi.org\/10.36740\/merkur202506104","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}